B+
Bull case
25%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
MNOV
MediciNovaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The stock is cheap versus its $67.8 million market cap and year-end cash base, COMBAT-ALS is already fully enrolled, SEANOBI adds external-data support, and even one credible partnership or favorable ALS update could re-rate shares sharply from depressed levels.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Equity issuance through the Lucid facility or other financings could pressure the stock before major data.
Momentum
85
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.60 · Bear $0.60Analysis 2026-04-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.0
Sentiment34 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Equity issuance through the Lucid facility or other financings could pressure the stock before major data.
- • Low coverage and sparse high-quality forward disclosures increase headline volatility and widen fair-value uncertainty.
- • Forward visibility is still weak, the thesis is concentrated in one major late-stage ALS readout, management explicitly acknowledges the need for additional development funding, and available equity facilities make dilution a realistic path if partnering does not arrive on attractive terms.
Catalyst clock
2026-09-30
Runway is adequate for roughly a year, but dilution remains a live overhang
Lead driver: Sentiment · See AI snapshot
Momentum
85
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
34
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 84.8 / Value 41.2 / Sentiment 33.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-22. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$64.97M
Beta
0.54
Shares Out
49.22M
P/E (TTM) · Derived
-5.4
P/S (TTM)
262.96
P/FCF (TTM) · Derived
-7.11
Rev YoY
+240.6%
EPS YoY
-29.7%
Gross Margin
+31.1%
Op Margin
-1287.4%
Net Debt
-$30.6M
Current Ratio
8.75
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data